Lung Cancer News and Research

Latest Lung Cancer News and Research

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Research may aid in developing new cancer therapies

Research may aid in developing new cancer therapies

FDA grants EUA for IQuum's Liat Influenza A/2009 H1N1 Assay

FDA grants EUA for IQuum's Liat Influenza A/2009 H1N1 Assay

QRxPharma reports successful outcome of Phase 1 trial for MoxDuo CR for chronic pain

QRxPharma reports successful outcome of Phase 1 trial for MoxDuo CR for chronic pain

Asthmatx announces first U.S. patient treated with BT delivered by Alair System

Asthmatx announces first U.S. patient treated with BT delivered by Alair System

MicroStockProfit.com features investment report on ARIAD Pharmaceuticals

MicroStockProfit.com features investment report on ARIAD Pharmaceuticals

UT Southwestern offers advanced lung-cancer patients free screenings of tumors for genetic mutations

UT Southwestern offers advanced lung-cancer patients free screenings of tumors for genetic mutations

Study: PDE5 inhibitors may increase permeability of blood brain barrier to Herceptin

Study: PDE5 inhibitors may increase permeability of blood brain barrier to Herceptin

Minimally invasive scopes to detect cancer

Minimally invasive scopes to detect cancer

ADDF awards $210,300 to Amicus Therapeutics to evaluate PCs for treating Alzheimer's disease

ADDF awards $210,300 to Amicus Therapeutics to evaluate PCs for treating Alzheimer's disease

Telik first-quarter net loss decreases to $5.3 million

Telik first-quarter net loss decreases to $5.3 million

Australia’s first ever health policy for men

Australia’s first ever health policy for men

Abraxis Bioscience first-quarter ABRAXANE revenue increases to $87.9 million

Abraxis Bioscience first-quarter ABRAXANE revenue increases to $87.9 million

ArQule reports net loss of $9,752,000 for first-quarter 2010

ArQule reports net loss of $9,752,000 for first-quarter 2010

Study aims to clarify expression patterns of CD24 in NSCLC

Study aims to clarify expression patterns of CD24 in NSCLC

VEGF is key target for new anti-angiogenesis drugs, Spanish team reports

VEGF is key target for new anti-angiogenesis drugs, Spanish team reports

New blood test could increase success of lung cancer drug erlotinib: Study

New blood test could increase success of lung cancer drug erlotinib: Study

Allos Therapeutics reports net loss of $20.5 million for first-quarter 2010

Allos Therapeutics reports net loss of $20.5 million for first-quarter 2010

Decreasing radiotherapy doses given to 'cold spots' can help reduce side-effects

Decreasing radiotherapy doses given to 'cold spots' can help reduce side-effects

Decisive impact of informatics on nanomedicine

Decisive impact of informatics on nanomedicine

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.